The US Food and Drug Administration (FDA) has approved four generic versions of Gilead Sciences’ Letairis (ambrisentan), an endothelin receptor antagonist indicated for treatment for pulmonary arterial hypertension (PAH).
The FDA first approved Letairis for PAH in 2007. Three generics are from Mylan Pharmaceuticals, Watson Laboratories, and Sun Pharma Global. The fourth generic is from Zydus Pharmaceuticals.
In order to accommodate all four generics, the FDA also approved two shared system risk evaluation and mitigation strategy (REMS) programs for generic ambrisentan, which means there are now two separate REMS programs for the drug.
One program called Ambrisentan REMS (formerly Letairis REMS) consists of the brand name drug (Letairis) for the three generics from Mylan, Watson, and Sun.
The other program for Zydus’ generic version is called PS-Ambrisentan REMS. The PS signifies “parallel system” to help differentiate the programs within the market, the FDA said.
The PS-Ambrisentan REMS allows ambrisentan to be filled in the retail setting, while the Ambrisentan REMS will continue to only utilize specialty pharmacies.
With the approval of these first generics, and their associated REMS programs, “patients will now have access to additional products (brand-name and generic) and additional types of pharmacies to fill their prescriptions (retail or specialty),” the FDA said in a statement.
For patients to have access to generic ambrisentan, prescribers need to take the following actions:
- Ensure patients are enrolled in both programs by enrolling in the PS-Ambrisentan REMS. Prescribers currently enrolled in the Letairis REMS will be automatically enrolled in the Ambrisentan REMS. This will allow patients to have access to both generic and branded ambrisentan and to receive their medication from multiple pharmacy types, depending on their insurance coverage.
- Enroll current ambrisentan patients in the PS-Ambrisentan REMS. Patients currently enrolled in the Letairis REMS will be automatically transferred to the Ambrisentan REMS.
- Enroll all future ambrisentan patients in both the Ambrisentan REMS and the PS-Ambrisentan REMS.
-GDMeds, an India Pharmacy Service company
[Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作，需遵守第三方的版权，特别是标示为第三方内容的。如用户发现侵犯版权的行为，请通知极得美。一旦收到违反通知，极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.